Majno P, Castaing D, Adam R, Savier E, Ghemard O, Bismuth H
Centre Hépato-Biliaire, Hôpital Paul-Bróusse, Villejuif.
Ann Chir. 1998;52(6):518-26.
Percutaneous ethanol injection treatment, introduced ten years ago as palliative therapy for patients with inoperable hepatocellular carcinoma, can now be used with a curative intent to treat small tumours with results comparable to surgical resection. This progress, made possible by sophisticated radiological techniques, makes percutaneous ethanol injection the treatment of choice for patients with poor liver function in whom resection is not possible and local control of the disease is desirable either for prolonged palliation or in view of liver transplantation. For patients with large tumours, or in case of recurrence after previous surgical treatment, a therapeutic approach combining transarterial lipiodol chemoembolisation and percutaneous ethanol injection has shown promising results and deserves further investigation.
经皮乙醇注射治疗十年前作为无法手术切除的肝细胞癌患者的姑息治疗方法被引入,现在可用于以治愈为目的治疗小肿瘤,其效果与手术切除相当。这种进展得益于先进的放射技术,使得经皮乙醇注射成为肝功能差、无法进行切除且希望通过延长姑息治疗或考虑肝移植来实现疾病局部控制的患者的首选治疗方法。对于大肿瘤患者,或既往手术治疗后复发的情况,经动脉碘油化疗栓塞和经皮乙醇注射相结合的治疗方法已显示出有希望的结果,值得进一步研究。